SAINTE-FOY, QUEBEC--(CCNMatthews - Nov. 29, 2006) - Bioxel Pharma Inc. (TSX VENTURE:BIP), a leading manufacturer of taxane active pharmaceutical ingredients (APIs) and developer of targeted oncology drugs, is pleased to announce that the Corporation has received repeat orders for its cGMP paclitaxel from two EU Customers. One is a leading European generic manufacturer; the second is a pharmaceutical company with a paclitaxel-based product in final stage of clinical development. Paclitaxel deliveries started at the end of the third quarter of 2006. The combined value of the orders is CAD $630,000.
